PixCell Medical Announces Acquisition by Soulbrain Holdings

Transaction Underscores PixCell's Leading Position in Disruptive Point-of-Care Testing Technology

News provided by

May 03, 2021, 08:00 ET

YOKNEAM ILIT, Israel, May 3, 2021 /PRNewswire/ -- PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that Soulbrain Holdings has acquired all controlling PixCell shares, as well as investing in the company, making Soulbrain the majority shareholder of PixCell Medical. The acquisition of PixCell aligns with Soulbrain's recent strategic transition into the healthcare and in-vitro diagnostics space.

Soulbrain, a leader in the semiconductor space, recently chose the bio-healthcare industry as an engine for growth and has already made several acquisitions and investments. The company identified PixCell as a good fit for its strategy of entering the diagnostics and point-of-care testing space, with a purpose of distributing specialized diagnostic reagents and miniaturized medical devices.

"We identified PixCell Medical as a company proven to have disruptive technology in the healthcare field and are proud to have them join the Soulbrain family," said Dr. Nam Huh, Head of Bio-Healthcare Division and Vice President at Soulbrain. "Striving to acquire technologies that will serve as the foundation of future industry development is our focus, and we have diversified our business portfolio to include distribution of specialized diagnostic reagents and miniaturized medical devices focused on point-of-care. Providing higher added value and satisfaction to our customers is our top priority, and PixCell is a great addition to our growing family of competitive life science daughter companies."

PixCell Medical's flagship product, HemoScreen™, is a point-of-care blood testing platform that can conduct blood cell analysis within five minutes by applying AI-driven novel microfluidic and lab-on-a-cartridge technology. FDA-cleared, CE-marked and TGA-approved, the HemoScreen reliably conducts five-part differential complete blood count (CBC) tests, producing results equivalent to laboratory analyzers in significantly less time. By applying a novel, patented microfluidics method called Viscoelastic Focusing to conduct the cell analysis, PixCell has miniaturized traditionally large and complex machinery.

"This deal is crucial for PixCell's global expansion and commercialization of the HemoScreen. We believe Soulbrain will be an excellent strategic partner, helping accelerate our growth while continuing to provide accessible and accurate hematological test results on a global scale," said Dr. Avishay Bransky, Co-Founder and CEO of PixCell Medical. "Our goal is to deliver reliable, simple and affordable diagnostic information to those in need – be it patients with chronic illnesses or people living in remote areas with lack of access to healthcare. Partnering with Soulbrain is an important milestone for us in achieving that goal."

About PixCell Medical

PixCell Medical provides the first truly portable point-of-care blood diagnostic solution. Leveraging the company's patented Viscoelastic Focusing technology, along with AI-powered machine vision, PixCell's FDA-cleared and CE-marked HemoScreen™ diagnostic platform shortens diagnostic results delivery from days to minutes. With just one drop of blood and within six minutes, PixCell delivers accurate readings of 20 standard blood count parameters, saving patients, clinicians and health systems significant time and costs.

For more information: www.pixcell-medical.com and follow PixCell on LinkedIn.

Media Contact:
Finn Partners for PixCell Medical
Lior Feigin
[email protected]
@LiorFeigin

SOURCE PixCell Medical